These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 1467385)
61. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445 [No Abstract] [Full Text] [Related]
62. Memory and plasma HVA changes in schizophrenia: are they episode markers? Gilbertson MW; Yao JK; van Kammen DP Biol Psychiatry; 1994 Feb; 35(3):203-6. PubMed ID: 8173021 [No Abstract] [Full Text] [Related]
63. Haloperidol does not affect the level of serum-soluble interleukin-2 receptor in drug-free male schizophrenics. Kim CE; Kang DY; Ha KS; Jeong SH; Kim YS Biol Psychiatry; 1995 Dec; 38(12):843-5. PubMed ID: 8750045 [No Abstract] [Full Text] [Related]
64. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Lieberman JA; Alvir J; Geisler S; Ramos-Lorenzi J; Woerner M; Novacenko H; Cooper T; Kane JM Neuropsychopharmacology; 1994 Oct; 11(2):107-18. PubMed ID: 7840862 [TBL] [Abstract][Full Text] [Related]
65. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables]. Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983 [TBL] [Abstract][Full Text] [Related]
66. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740 [TBL] [Abstract][Full Text] [Related]
67. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects. Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612 [TBL] [Abstract][Full Text] [Related]
68. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Kane JM; Rifkin A; Woerner M; Reardon G; Sarantakos S; Schiebel D; Ramos-Lorenzi J Arch Gen Psychiatry; 1983 Aug; 40(8):893-6. PubMed ID: 6347119 [TBL] [Abstract][Full Text] [Related]
69. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation. Soni SD; Sampath G; Shah A; Krska J Acta Psychiatr Scand; 1992 May; 85(5):354-9. PubMed ID: 1351333 [TBL] [Abstract][Full Text] [Related]
78. Study of the clinical utility of radioreceptor assay in outpatients with schizophrenia receiving high doses of neuroleptics. Gagné MA; Cormier H; Leblanc G; Lévesque D; Di Paolo T Can J Psychiatry; 1993 Oct; 38(8):534-40. PubMed ID: 7902199 [TBL] [Abstract][Full Text] [Related]
79. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Kane JM; Davis JM; Schooler N; Marder S; Casey D; Brauzer B; Mintz J; Conley R Am J Psychiatry; 2002 Apr; 159(4):554-60. PubMed ID: 11925292 [TBL] [Abstract][Full Text] [Related]
80. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships. van Kammen DP; Guidotti A; Kelley ME; Gurklis J; Guarneri P; Gilbertson MW; Yao JK; Peters J; Costa E Biol Psychiatry; 1993 Oct; 34(8):515-22. PubMed ID: 8274578 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]